Search - tctmd.com

Displaying 641 - 660 of 952

Sort: Relevancy | Date

News Industry News

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

October 25, 2012

Presentation TCT 2012

Contrarian Position: Get Your Heads Out of the Sand! Genomics and Platelet Function Testing Will Revolutionize Tailored Antiplatelet Therapy!

Presenter: Matthew Price

October 24, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Presentation TCT 2012

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

Presenter: Marco Valgimigli

October 24, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Conference News TCT 2012

Promising Outlook for Bioabsorbable Scaffolds, Polymers in Next-Generation Stents

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

News Conference News TCT 2012

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

October 24, 2012

News Conference News TCT 2012

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

October 23, 2012

News Industry News

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

October 23, 2012

News Conference News TCT 2012

DES: The Year in Review

October 23, 2012

News Conference News TCT 2012

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

October 23, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

News Industry News

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

October 22, 2012

News Daily News

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

October 19, 2012

News Industry News

FDA expands approved use of Sapien artificial heart valve

October 19, 2012

News Industry News

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

October 12, 2012

News Daily News

Almost 1 in 10 STEMIs Caused by Stent Thrombosis

October 12, 2012

News Daily News

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

Jason Kahn

October 05, 2012

News Daily News

Apixaban Surpasses Warfarin At All Risk Levels in A-Fib Patients

Caitlin E. Cox

October 04, 2012

Advertisement

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

Contrarian Position: Get Your Heads Out of the Sand! Genomics and Platelet Function Testing Will Revolutionize Tailored Antiplatelet Therapy!

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

Promising Outlook for Bioabsorbable Scaffolds, Polymers in Next-Generation Stents

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

DES: The Year in Review

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

FDA expands approved use of Sapien artificial heart valve

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

Almost 1 in 10 STEMIs Caused by Stent Thrombosis

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

Apixaban Surpasses Warfarin At All Risk Levels in A-Fib Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content